Thu, April 4, 2013
Wed, April 3, 2013

Evan Seigerman Maintained (BIIB) at Buy with Increased Target to $225 on, Apr 4th, 2013

Evan Seigerman of Credit Suisse, Maintained "Biogen Inc." (BIIB) at Buy with Increased Target from $200 to $225 on, Apr 4th, 2013.

Evan has made no other calls on BIIB in the last 4 months.



There are 5 other peers that have a rating on BIIB. Out of the 5 peers that are also analyzing BIIB, 2 agree with Evan's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Christopher Raymond of "Piper Sandler" Downgraded from Buy to Hold and Decreased Target to $166 on, Thursday, January 3rd, 2013
  • Jay Olson of "Oppenheimer" Maintained at Hold with Decreased Target to $141 on, Thursday, January 3rd, 2013


These are the ratings of the 3 analyists that currently disagree with Evan


  • Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $206 on, Monday, April 1st, 2013
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $188 on, Monday, March 25th, 2013
  • Andrew Peters of "Deutsche Bank" Maintained at Strong Buy with Increased Target to $170 on, Wednesday, February 6th, 2013


Similar Stocks and Investing Publications